Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial. [electronic resource]
Producer: 20090302Description: 228-36 p. digitalISSN:- 1460-2105
- Aged
- Androgen Antagonists -- administration & dosage
- Antineoplastic Agents, Hormonal -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor -- blood
- Chemotherapy, Adjuvant
- Disease-Free Survival
- Dose Fractionation, Radiation
- Endpoint Determination -- methods
- Flutamide -- administration & dosage
- Follow-Up Studies
- Goserelin -- administration & dosage
- Humans
- Karnofsky Performance Status
- Male
- Middle Aged
- Neoadjuvant Therapy -- methods
- Neoplasms, Hormone-Dependent -- blood
- Prostate-Specific Antigen -- blood
- Prostatic Neoplasms -- blood
- Radiotherapy, Adjuvant
- Research Design
- Treatment Failure
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.